488706-08-7

Upstream product

• 67764-22-1 4-heptylmethane sulphonate 
• 188911-53-7 1-(4-Methoxy-benzyl)-3-methyl-urea 
• 56651-60-6 4-methoxybenzyl isocyanate 
• 54052-68-5 6-amino-1-(4-methoxy-benzyl)-3-methyl-5-nitroso-1H-pyrimidine-2,4-dione 
• 54099-72-8 5,6-diamino-1-(4-methoxy-benzyl)-3-methyl-1H-pyrimidine-2,4-dione 
• 54052-70-9 6-amino-1-(4-methoxy-benzyl)-3-methyl-1H-pyrimidine-2,4-dione 

Downstream Products

• 756481-52-4 8-ethyl-7-(4-heptyl)-3-(4-methoxybenzyl)-1-methyl-1,2,3,7-tetrahydro-6H-purin-6-one 
• 756481-66-0 3-(4-chloro-phenyl)-8-ethyl-1-methyl-7-(1-propyl-butyl)-3,7-dihydro-purine-2,6-dione 
• 756481-51-3 2-ethyl-1-(4-heptyl)-4-[(4-methoxybenzyl)amino]-N-methyl-1H-imidazole-5-carboxamide 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6H- purin-6-one and 3,7-dihydro-1H-purine-2,6-dione derivatives as corticotropin-releasing factor1 receptor antagonists

A growing body of evidence suggests that CRF1 receptor antagonism offers considerable therapeutic potential in the treatment of diseases resulting from elevated levels of CRF, such as anxiety and depression. A series of novel 1,2,3,7-tetrahydro-6H-purin-6-one and 3,7-dihydro-1H-purine-2, 6-dione derivatives was synthesized and evaluated as corticotropin releasing factor-1 (CRF1) receptor antagonists. Compounds within this series, represented by compound 12d (IC50 = 5.4 nM), were found to be highly potent CRF1 receptor antagonists. In addition, compounds 12d and 12j were determined to be selective CRF1 antagonists. The synthesis, structure-activity relationships and pharmacokinetic properties of compounds within this series is presented.

3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands

Compounds provided herein are 3,7-dihydro-purine-2,6-dione derivatives of Formula (I): Such compounds are particularly useful as CRF receptor ligands, and hence, in the treatment of various neurologically-related disorders such as affective disorder, anxi